<?xml version="1.0" encoding="UTF-8"?>
<p>Human clinical trials have been used to assess no pharmacological strategies to prevent flavivirus infection. There are no current treatments available for DENV infection. In 2016, a clinical trial testing celgosivir, an endoplasmic reticulum alpha glucosidase inhibitor; failed to demonstrate antiviral efficacy (lower viremia) in Asia (Sung et al., 
 <xref rid="B203" ref-type="bibr">2016</xref>). Similarly, in the same year, lovastatin showed no power to address efficacy in Vietnam (Whitehorn et al., 
 <xref rid="B230" ref-type="bibr">2016</xref>). A protocol of fluid resuscitation with hypertonic sodium lactate showed similar efficacy compared to the Ringer Lactate in patients in Indonesia with dengue shock syndrome, based on rate of recovery (Somasetia et al., 
 <xref rid="B196" ref-type="bibr">2014</xref>).
</p>
